Dehydroabietic acid (DHA or DAA), a diterpene, is obtained from Commiphora oppbalsamum. DHA has potential as treatment for obesity and metabolic syndrome, obese diabetic KK-Ay mice treated with DHA showed decreased plasma glucose, insulin, and triglyceride levels. It has been reported that DHA inhibits the production of proinfammatory mediators such as TNF-α in macrophages and adipocytes and causes endothelium-dependent relaxation of pulmonary artery via PI3K/Akt-eNOS signaling pathway. Also was shown, that DHA could reverse several cell responses stimulated by TNF-α, including the activation of FOXO1 and the TGF-β1/Smad3 signaling pathway. Thus, DAA could be useful in improving the diabetic wound healing.

Benzohydroxamic acid is a bidentate chelating agent. Benzohydroxamic acid is known to be competitive inhibitors of a variety of plant and animal peroxidases. Benzohydroxamic acid did not show a bactericidal effect against Helicobacter pylori despite moderate inhibition of urease activity. Benzohydroxamic acid is used for the synthesis of histone deacetylase inhibitors. Benzohydroxamic acid derivatives demonstrated the antineoplastic and cytotoxicity in murine and human tumor cells.